Table 3. Treatment response characteristics of patients treated with plitidepsin.
| Gender/age (years) | MF type | ECOG PS BL/WPC | Plitidepsin cycles | Best responsea | PFS /OS (months) |
Plt/RBC transfusion (units) |
Spleen reductionb (%) | |
|---|---|---|---|---|---|---|---|---|
| Baseline | On treatment | |||||||
| Male/77 | Post PV | 1/2 | 4 | Clinical improvementc | 4.6/4.6 | 0/2 | 0/0 | 21.4 |
| Female/67 | Post ET | 1/2 | 1 | SD | 0.9+/1.7+ | 0/1 | 1/1 | 0.0 |
| Female/68 | Post ET | 1/2 | 4 | SD | 3.6+/4.5+ | 0/2 | 0/2 | 22.2 |
| Female/64 | PMF | 1/1 | 2 | SD | 1.0+/1.7+ | 0/2 | 0/3 | 11.1 |
| Female/67 | PMF | 0/1 | 3 | SD | 1.8+/5.1+ | 0/1 | 0/2 | ND |
| Male/72 | PMF | 1/3 | 2 | SD | 2.3+/2.3+ | 0/2 | 0/4 | 35.0 |
| Male/73 | Post PV | 1/1 | 2 | SD | 1.9+/2.1+ | 1/2 | 0/10 | 53.3 |
| Male/71 | PMF | 2/2 | 2 | SD | 2.0+/2.0+ | 0/2 | 0/7 | 10.5 |
| Male/64 | PMF | 0/0 | 3 | SD | 2.8+/3.8+ | 0/0 | 0/10 | 7.7 |
| Female/78 | Post PV | 0/1 | 2 | SD | 1.8+/4.8+ | 0/0 | 0/0 | 22.2 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IWG-MRT, International Working Group for Myelofibrosis Research and Treatment; MF, myelofibrosis; ND, not determined; OS, overall survival; PFS, progression-free survival; Plt, platelet; post-ET, post-essential thrombocythaemia; post-PV, post-polycythaemia vera; PMF, primary myelofibrosis; PS, performance status; RBC, red blood cell; SD, stable disease; WPC, worst per cycle.
a
Best response as per IWG-MRT.
b
Maximal reduction from baseline by spleen palpation, which was reached within the first two cycles and persisted less than 8 weeks in all patients measured.
c
Time to response was 1.9 months.
+: Censored data.